Full text PDF - International Policy Network

294 Fighting the Diseases of Poverty
Gambardella, A., Orsenigo, L. & Pammolli, P., (2000), Global competitiveness in
pharmaceuticals: a European Perspecitve, Paper prepared for the Enterprise
Directorate-General of the European Commission, November.
Giacotto, C., (2004), “Explaining pharmaceutical R&D growth rates at the industry
level: new perspectives and insights,” AEI- Brookings Joint Centre for Regulatory
Studies.
IFPMA (2004), The Pharmaceutical Innovation Platform, Geneva
Kimani, D., (2005), “Malaria, HIV, TB, Diabetes Drugs to Cost 10 per cent more,” The
East African, 24 January. At: http://allafrica.com/stories/200501260090.html.
Kremer, M. & Glennerster, R., (2004), Strong Medicine, Princeton University Press:
Princeton.
Kumarasamy, N., (2004), “Generic antiretroviral drugs – will they be the answer to
HIV in the developing world?” The Lancet, vol 364.
Lichtenberg, F., (2003), “The value of new drugs,” Milken Institute Review, Fourth
Quarter, 2003.
Maskus, K., (2000), Intellectual Property in the global economy, Institute for
International Economics, Washington DC.
Menon, D., (2001), “Pharmaceuticals cost control in Canada: Does it work?” Health
Affairs, 20(3) 92–103.
Padma, T., (2005), “India’s drug tests,” Nature, 436, 485. 28 July 2005.
Poisal, J. & Chulis, G., (2000), “Medicare beneficiaries and drug coverage,” Health
Affairs, 19(2).
Rawlins, M., (2004), “Cutting the cost of drug development?” Nature, 3:360.
Reekie, D.W., (1997), “How Competition Lowers the Cost of Medicines,” Cuadernos de
Derects Europeu Farmaceutico, 3(8): 35–48. Reprinted in Pharmacoeconomics,
14:107–113.
Rozek, R., (2000), “The effects of compulsory licensing on innovation and access to
healthcare,” NERA, September.
Saleh, K. & Ibrahim, M., (2005), “Are Essential Medicines in Malaysia Accessible,
Affordable and Available?” Pharmacy World & Science, 27:6 442–446.
Sauer, R. & Sauer, C., (2005), “Reducing Barrier to the Development of High Quality,
Low Cost Medicines: A Proposal for Reforming the Drug Approval Process,”
London: International Policy Press.
Shaw, R. & Ainswoth, M., (1995), “Financing heath services through user fees and
insurance,” World Bank, discussion paper 294.
Sherwood, R., (2000), “The economic importance of judges,” Federal Circuit Bar
Journal, 9(4): 619–633.
Soderlund, N. & Hansl, B., (2000), “Health Insurance in South Africa: an empirical
analysis of trends in risk-pooling and efficiency following deregulation,” Health
Policy and Planning, 15(4):378–385.
UNAIDS, (2006), 2006 Report on the global AIDS epidemic, UNAIDS, Geneva, available at
http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp
U.S. Department of Commerce, (2004), “Pharmaceutical price controls in OECD
Countries: implications for US consumers, pricing, research and development,
and innovation,” International Trade Administration, December.
Wofford, D., & Shanahan, C., (2004), Doing Business in 2005, World Bank.